Login to Your Account



AN ‘INCREMENTAL POSITIVE’ FOR BIOGEN IDEC?

In the multiple sclerosis race, others ‘Campath’ Genzyme: FDA delivers CRL

By Randy Osborne
Staff Writer

Tuesday, December 31, 2013
Though not a huge surprise, the complete response letter (CRL) from the FDA for Lemtrada (alemtuzumab) sent a rumble through the multiple sclerosis (MS) therapy space, and shook investors in Genzyme Corp., which has been told by the agency that approval of the CD52-targeting antibody requires more trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription